JP6695347B2 - レトロウイルスおよびレンチウイルスベクター - Google Patents

レトロウイルスおよびレンチウイルスベクター Download PDF

Info

Publication number
JP6695347B2
JP6695347B2 JP2017545941A JP2017545941A JP6695347B2 JP 6695347 B2 JP6695347 B2 JP 6695347B2 JP 2017545941 A JP2017545941 A JP 2017545941A JP 2017545941 A JP2017545941 A JP 2017545941A JP 6695347 B2 JP6695347 B2 JP 6695347B2
Authority
JP
Japan
Prior art keywords
cell
vector
mitogenic
retroviral
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017545941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506983A5 (enExample
JP2018506983A (ja
Inventor
マーティン プーレ，
マーティン プーレ，
レイラ メッカオウイ，
レイラ メッカオウイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52876362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6695347(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of JP2018506983A publication Critical patent/JP2018506983A/ja
Publication of JP2018506983A5 publication Critical patent/JP2018506983A5/ja
Application granted granted Critical
Publication of JP6695347B2 publication Critical patent/JP6695347B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/852—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from cytokines; from lymphokines; from interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017545941A 2015-03-02 2016-03-01 レトロウイルスおよびレンチウイルスベクター Active JP6695347B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1503500.9 2015-03-02
GB201503500A GB201503500D0 (en) 2015-03-02 2015-03-02 Cell
PCT/GB2016/050537 WO2016139463A1 (en) 2015-03-02 2016-03-01 Retroviral and lentiviral vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020050861A Division JP2020092722A (ja) 2015-03-02 2020-03-23 レトロウイルスおよびレンチウイルスベクター

Publications (3)

Publication Number Publication Date
JP2018506983A JP2018506983A (ja) 2018-03-15
JP2018506983A5 JP2018506983A5 (enExample) 2019-01-24
JP6695347B2 true JP6695347B2 (ja) 2020-05-20

Family

ID=52876362

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017545941A Active JP6695347B2 (ja) 2015-03-02 2016-03-01 レトロウイルスおよびレンチウイルスベクター
JP2020050861A Withdrawn JP2020092722A (ja) 2015-03-02 2020-03-23 レトロウイルスおよびレンチウイルスベクター
JP2023029559A Pending JP2023060000A (ja) 2015-03-02 2023-02-28 レトロウイルスおよびレンチウイルスベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020050861A Withdrawn JP2020092722A (ja) 2015-03-02 2020-03-23 レトロウイルスおよびレンチウイルスベクター
JP2023029559A Pending JP2023060000A (ja) 2015-03-02 2023-02-28 レトロウイルスおよびレンチウイルスベクター

Country Status (16)

Country Link
US (2) US10954530B2 (enExample)
EP (2) EP3265570B2 (enExample)
JP (3) JP6695347B2 (enExample)
KR (1) KR20180002602A (enExample)
CN (1) CN107406860A (enExample)
AU (1) AU2016227474A1 (enExample)
BR (1) BR112017018251A2 (enExample)
CA (1) CA2977472A1 (enExample)
CL (1) CL2017002199A1 (enExample)
ES (1) ES2877398T5 (enExample)
GB (1) GB201503500D0 (enExample)
IL (1) IL253820B (enExample)
MX (1) MX2017010553A (enExample)
RU (1) RU2017133854A (enExample)
SG (1) SG11201706721PA (enExample)
WO (1) WO2016139463A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802728T4 (tr) 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
PE20180241A1 (es) 2015-04-30 2018-01-31 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7
US10046317B2 (en) * 2015-08-11 2018-08-14 Chevron U.S.A. Inc. Middle distillate hydrocracking catalyst containing zeolite beta with low OD acidity and large domain size
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
KR102857666B1 (ko) 2015-12-17 2025-09-10 아카미스 바이오 리미티드 항-tcr-복합체 항체 또는 단편을 암호화하는 군 b 아데노바이러스
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
SG10202104509PA (en) * 2016-03-19 2021-06-29 Exuma Biotech Corp Methods and compositions for transducing lymphocytes and regulated expansion thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
GB201614093D0 (en) * 2016-08-17 2016-09-28 Autolus Ltd Vector
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
AU2017320776B2 (en) 2016-08-29 2024-10-10 Akamis Bio Limited Adenovirus armed with bispecific T cell activator
US20190350978A1 (en) * 2016-12-05 2019-11-21 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
EP3564265A4 (en) * 2016-12-30 2021-02-17 Cytocares (Shanghai) Inc. Trifunctional molecule and application thereof
BR112019018288A2 (pt) * 2017-03-03 2020-03-31 F1 Oncology, Inc. Métodos e composições para transduzir e expandir linfócitos e regular a atividade dos mesmos
JP7039623B2 (ja) * 2017-05-26 2022-03-22 グリーン・クロス・ラブ・セル・コーポレイション 形質転換されたｔ細胞を用いてナチュラルキラー細胞を培養する方法
CN118895313A (zh) * 2017-09-18 2024-11-05 埃克苏马生物技术公司 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物
JP7262465B2 (ja) * 2017-12-20 2023-04-21 ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー Ｎｋ細胞形質導入のための方法
SG11202009975TA (en) 2018-04-12 2020-11-27 Umoja Biopharma Inc Viral vectors and packaging cell lines
US20210301260A1 (en) * 2018-08-10 2021-09-30 Kyoto University Method for producing cd3-positive cell
JP7672187B2 (ja) * 2018-09-02 2025-05-07 エクスマ バイオテック コーポレイション 血液中または濃縮ｐｂｍｃ中のリンパ球を遺伝子改変するための方法および組成物
SG11202104662UA (en) 2018-11-14 2021-06-29 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t-cells
EP3884058A1 (en) 2018-11-21 2021-09-29 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
CN109722420A (zh) * 2019-03-15 2019-05-07 江苏艾洛特医药研究院有限公司 一种改良嵌合抗原受体t细胞的制备及其应用
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
JP2022553200A (ja) * 2019-10-16 2022-12-22 ウモジャ バイオファーマ， インコーポレイテッド ユニバーサル受容体療法のためのレトロウイルスベクター
CN115697388A (zh) 2020-01-30 2023-02-03 优莫佳生物制药股份有限公司 双特异性转导增强子
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
CN116745427A (zh) 2020-11-20 2023-09-12 优莫佳生物制药股份有限公司 用于递送多种多核苷酸的载体系统及其用途
JP2024505887A (ja) 2021-01-27 2024-02-08 ウモジャ バイオファーマ， インコーポレイテッド 抗ｃｄ１９キメラ抗原受容体を発現する細胞を生成するためのレンチウイルス
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
AU2023212736A1 (en) * 2022-01-25 2024-08-01 Sunshine Lake Pharma Co., Ltd. Viral vector and application thereof
WO2023198828A1 (en) 2022-04-13 2023-10-19 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
IL316839A (en) 2022-05-17 2025-01-01 Umoja Biopharma Inc Production of viral particles
AU2023371650A1 (en) 2022-11-04 2025-05-29 Umoja Biopharma, Inc. Polynucleotide construct and related viral vectors and methods
WO2024098028A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Lentiviral particles displaying fusion molecules and uses thereof
WO2024097992A2 (en) 2022-11-04 2024-05-10 Umoja Biopharma, Inc. Particles displaying adhesion-molecule fusions
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024179465A1 (zh) * 2023-02-27 2024-09-06 上海君赛生物科技有限公司 表达膜结合细胞因子的肿瘤浸润淋巴细胞
WO2024223847A1 (en) * 2023-04-27 2024-10-31 Miltenyi Biotec B.V. & Co. KG Pseudotyped retroviral vector particle with anti-cd3 display
WO2024238153A1 (en) 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
CN116496417B (zh) * 2023-06-27 2023-10-10 北京市肿瘤防治研究所 含有膜型il7的融合蛋白及t细胞
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
US12269882B1 (en) 2023-09-25 2025-04-08 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer
WO2025072257A1 (en) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Compositions for treating cancer
WO2025090978A1 (en) 2023-10-26 2025-05-01 Cargo Therapeutics, Inc. Modified immune effector cells
WO2025149068A1 (zh) * 2024-01-10 2025-07-17 深圳市济因生物科技有限公司 一种病毒颗粒及其制备方法与应用
WO2025231174A1 (en) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Manufacturing viral particles
WO2025235604A1 (en) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Fusion protein for use as immune cell engager
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027643A1 (en) * 1993-06-01 1994-12-08 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
AU727531B2 (en) * 1995-07-25 2000-12-14 Crucell Holland B.V. Methods and means for targeted gene delivery
WO2004080404A2 (en) 2003-03-07 2004-09-23 University Of Utah Research Foundation Il-2 transmembrane constructs
CA2572467A1 (en) * 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
WO2007095201A2 (en) * 2006-02-15 2007-08-23 The Regents Of The University Of California Pseudotyped retroviral vectors and methods of use thereof
US8293685B2 (en) * 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
GB0920775D0 (en) * 2009-11-26 2010-01-13 King S College Cells
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
GB201614093D0 (en) 2016-08-17 2016-09-28 Autolus Ltd Vector
GB201910651D0 (en) 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle

Also Published As

Publication number Publication date
JP2023060000A (ja) 2023-04-27
SG11201706721PA (en) 2017-09-28
AU2016227474A1 (en) 2017-08-31
US20180066280A1 (en) 2018-03-08
IL253820B (en) 2021-03-25
EP3265570B1 (en) 2021-05-05
EP3265570B2 (en) 2025-07-23
US11814641B2 (en) 2023-11-14
EP3265570A1 (en) 2018-01-10
WO2016139463A1 (en) 2016-09-09
RU2017133854A (ru) 2019-04-02
CN107406860A (zh) 2017-11-28
CA2977472A1 (en) 2016-09-09
CL2017002199A1 (es) 2018-03-16
EP3904523A1 (en) 2021-11-03
ES2877398T3 (es) 2021-11-16
JP2018506983A (ja) 2018-03-15
US10954530B2 (en) 2021-03-23
US20210348191A1 (en) 2021-11-11
IL253820A0 (en) 2017-09-28
MX2017010553A (es) 2018-03-15
BR112017018251A2 (pt) 2018-04-10
RU2017133854A3 (enExample) 2019-07-30
JP2020092722A (ja) 2020-06-18
GB201503500D0 (en) 2015-04-15
KR20180002602A (ko) 2018-01-08
ES2877398T5 (en) 2025-12-02

Similar Documents

Publication Publication Date Title
JP6695347B2 (ja) レトロウイルスおよびレンチウイルスベクター
US20240093232A1 (en) Retroviral And Lentiviral Vectors
JP7559029B2 (ja) 形質導入のための方法、キット、作用物質および装置
CN111479921B (zh) 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物
RU2755059C2 (ru) Способы и составы для производства лимфоцитов и их регулируемого увеличения
US20230407330A1 (en) Vector system for delivery of multiple polynucleotides and uses thereof
CN110526983B (zh) 改良型抗cd19 car-t细胞
JP2024503027A (ja) Ｃｄ８標的ウイルスベクターの使用方法
JP2018502583A (ja) 修飾された肝炎転写後調節エレメント
US20220249566A1 (en) Virus-like particle
US20220042039A1 (en) Improved lentiviral vector
CN102046780A (zh) 转染的细胞的生产方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200421

R150 Certificate of patent or registration of utility model

Ref document number: 6695347

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250